Edition:
United States

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

6.79USD
15 Aug 2018
Change (% chg)

$-0.41 (-5.69%)
Prev Close
$7.20
Open
$7.20
Day's High
$7.20
Day's Low
$6.48
Volume
80,107
Avg. Vol
121,236
52-wk High
$15.27
52-wk Low
$5.32

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Q4 Loss Per Share $0.65
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.65.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Clearside Proposes Public Offering Of $75 Mln Of Shares
Tuesday, 6 Mar 2018 04:00pm EST 

March 6 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CLEARSIDE BIOMEDICAL INC SAYS IT INTENDS TO OFFER AND SELL $75 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.CLEARSIDE BIOMEDICAL INC - ‍INTENDS TO OFFER $75 MILLION SHARES OF ITS COMMON STOCK IN PUBLIC OFFERING​.  Full Article

Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion
Tuesday, 6 Mar 2018 07:30am EST 

March 6 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION.CLEARSIDE BIOMEDICAL INC - ‍NOW EXPECTS TO REPORT PRELIMINARY DATA FROM SAPPHIRE TRIAL IN Q4 OF 2018 INSTEAD OF Q1 OF 2019​.CLEARSIDE BIOMEDICAL - ‍IF PRIMARY ENDPOINTS MET IN BOTH TOPAZ AND SAPPHIRE TRIALS, CO EXPECTS TO SEEK AGNOSTIC LABEL IN U.S..  Full Article

Clearside Biomedical Announces Results From Phase 3 Trial Of CLS-TA
Monday, 5 Mar 2018 07:00am EST 

March 5 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF CLS-TA IN MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS.PRIMARY ENDPOINT ACHIEVED IN PHASE 3 CLINICAL TRIAL OF CLS-TA.ALL KEY SECONDARY ENDPOINTS ACHIEVED IN STUDY.STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROPORTION OF PATIENTS GAINING 15 OR MORE LETTERS IN VISUAL ACUITY IN STUDY.SUPRACHOROIDAL CLS-TA WAS GENERALLY WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED IN TRIAL.EXPECT TO SUBMIT NDA FOR SUPRACHOROIDAL CLS-TA IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH UVEITIS TO FDA IN Q4 2018.EVALUATING OPTIONS FOR SUBMISSIONS TO REGULATORY AGENCIES IN TERRITORIES OUTSIDE OF U.S. FOR SUPRACHOROIDAL CLS-TA.  Full Article

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
Tuesday, 24 Oct 2017 04:30pm EDT 

Oct 24 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema.Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​.  Full Article

Clearside Biomedical reports Q2 loss per share $0.54
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Clearside Biomedical Inc :Announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.54.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Clearside biomedical - ‍cash, cash equivalents and short-term investments totaled $66.0 million as of june 30, compared to $83.6 million as of dec 31, 2016​.  Full Article

Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA
Monday, 7 Aug 2017 08:00am EDT 

Aug 7 (Reuters) - Clearside Biomedical Inc ::Announces completion of patient enrollment in pivotal Phase 3 Peachtree Clinical Trial of CLS-TA for Suprachoroidal administration in patients with Macular Edema associated with non-infectious Uveitis.Co currently expects to report top-line results from trial in Q1 of 2018.  Full Article

Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA
Tuesday, 11 Jul 2017 04:30pm EDT 

July 11 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema.Clearside Biomedical Inc - currently expect to report three-month preliminary data in first half of 2018.  Full Article

Clearside Biomedical files for mixed shelf offering of up to $250 mln - SEC Filing‍​ ‍​
Monday, 3 Jul 2017 06:25am EDT 

July 3 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical Inc files for mixed shelf offering of up to $250 million - SEC Filing‍​ ‍​.  Full Article

BRIEF-Clearside Biomedical Q1 Loss Per Share $0.62

* CLEARSIDE BIOMEDICAL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE